Comparison of clinical characteristics between patients with single mutation and co-mutation in hereditary renal cancer: a retrospective analysis of 115 patients with von Hippel-Lindau syndrome.

Clinical comparison between VHL patients with isolated VHL mutation vs germline co-mutations in other hereditary RCC predisposition genes (39-gene panel) — impact on penetrance and tumor aggressiveness

Among 115 VHL syndrome patients, 42.6% had germline co-mutations in other hereditary renal cancer predisposition genes (39-gene panel). The co-mutation group shows higher RCC penetrance (79.6% vs 57.6%, p=0.013) and pancreatic cystic tumor penetrance (77.6% vs 48.5%, p=0.002), and a higher proportion of symptomatic patients. Renal lesions showed significantly faster growth kinetics in the co-mutation group. Co-mutation status is an independent predictor of RCC development (HR 1.798, p=0.016).

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The surprisingly high frequency of 42.6% co-mutations in VHL syndrome invites integrating a multi-gene panel at initial workup — not yet standard practice. Faster tumor growth kinetics data argue for shorter surveillance intervals in these patients. For clinicians: a VHL patient with a co-mutation is not a 'standard' VHL patient and warrants differentiated management.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 0/2 · Sample size: 1/1 · Journal quality: 1/1 → Total: 6/10